Non-viral gene therapies may ease some safety, pricing and manufacturing challenges linked to viral vectors, but experts say both approaches will still have a place.

Peptide ligands can remove process- and product-related impurities from gene therapies better than protein ligands.

Switzerland's DINAMIQS receives Swissmedic approval for GMP viral vector production, becoming the country's first fully ...

Rebar will focus on establishing a pipeline of in vivo CAR T therapeutic programs based on the company’s proprietary immune-quiet DNA vector ...

HydroGene Therapeutics is a biotechnology company creating accessible gene therapies for all liver diseases. HydroGene is ...

Advanced non-viral gene delivery systems are expanding the range of indications and therapy modalities possible for the new generation of genetic medicines.

Aldevron, a Danaher company and global leader in the production of DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing ...

High-throughput virology, design of experiments, and small-molecule production enhancers optimize yield and increase ...

The AAV vector manufacturing market is mainly fueled by the expanding landscape of gene therapy research and development, as AAV vectors are extensively utilized for therapeutic gene delivery because ...

Transfection-free stable producer cell line (SCL) offers easy scalability, reduction of cost of goods (COGs), improve vector ...

Porton Advanced has announced that its proprietary stem cell-derived exosomes have been officially listed under the International ...